New and Emerging Therapies for MDS | Aplastic Anemia & MDS International Foundation

New and Emerging Therapies for MDS

Topic(s): 
Myelodysplastic Syndromes (MDS)
Presentation Date: 
Wednesday, September 30, 2020

Amit K. Verma, MBBS, is a Professor in the Departments of Medicine (Oncology) and Development & Molecular Biology at Albert Einstein School of Medicine. Dr. Verma is the Director of the Division of Hemato-Oncology, Montefiore Department of Oncology. His primary area of research is in MDS.

Amer Zeidan, MBBS, MHS is an Associate Professor of Medicine (Hematology) at the Yale School of Medicine. Dr. Zeidan specializes in the management of MDS and acute myeloid leukemia (AML) and is an international expert in the clinical management and research of myeloid malignancies.

Dr. Verma and Dr. Zeidan give an update on the two newest treatments for MDS patients, INQOVI and REBLOYZL. They also give a brief update on what is in the immediate pipeline for MDS patients and what can be expected into 2021.